These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 37994832)

  • 1. Sodium nitroprusside as an adjunctive treatment for schizophrenia reduces the Ndel1 oligopeptidase activity.
    Nani JV; Ushirohira JM; Bradshaw NJ; Machado-de-Sousa JP; Hallak JEC; Hayashi MAF
    Braz J Psychiatry; 2023 Nov; 46():. PubMed ID: 37994832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of NDEL1 oligopeptidase activity in blood and brain in an animal model of schizophrenia: effects of psychostimulants and antipsychotics.
    Nani JV; Lee RS; Yonamine CM; Sant'Anna OA; Juliano MA; Gadelha A; Mari JJ; Hayashi MAF
    Sci Rep; 2020 Oct; 10(1):18513. PubMed ID: 33116174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma Ndel1 enzyme activity is reduced in patients with schizophrenia--a potential biomarker?
    Gadelha A; Machado MF; Yonamine CM; Sato JR; Juliano MA; Oliveira V; Bressan RA; Hayashi MA
    J Psychiatr Res; 2013 May; 47(5):657-63. PubMed ID: 23388542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein-Protein and Peptide-Protein Interactions of NudE-Like 1 (Ndel1): A Protein Involved in Schizophrenia.
    Hayashi MA; Felicori LF; Fresqui MA; Yonamine CM
    Curr Protein Pept Sci; 2015; 16(8):754-67. PubMed ID: 25961396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unraveiling the correlation among neurodevelopmental and inflammatory biomarkers in patients with chronic schizophrenia.
    Nani JV; Almeida PGC; Noto C; Bressan RA; Brietzke E; Hayashi MAF
    Nord J Psychiatry; 2022 Oct; 76(7):559-564. PubMed ID: 36189960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genome-wide investigation of schizophrenia associated plasma Ndel1 enzyme activity.
    Gadelha A; Coleman J; Breen G; Mazzoti DR; Yonamine CM; Pellegrino R; Ota VK; Belangero SI; Glessner J; Sleiman P; Hakonarson H; Hayashi MA; Bressan RA
    Schizophr Res; 2016 Apr; 172(1-3):60-7. PubMed ID: 26851141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ndel1 oligopeptidase activity as a potential biomarker of early stages of schizophrenia.
    Dal Mas C; Nani JV; Noto C; Yonamine CM; da Cunha GR; Mansur RB; Ota VK; Belangero SI; Cordeiro Q; Kapczinski F; Brietzke E; Bressan RA; Gadelha A; Hayashi MAF
    Schizophr Res; 2019 Jun; 208():202-208. PubMed ID: 30857875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of an ex vivo inhibitor of the schizophrenia biomarker Ndel1 by high throughput screening.
    Nani JV; Coelho C; Oyadomari WY; Santiago TC; Machado MM; Christoff RR; Garcez PP; Oliveira V; Würtele M; Hayashi MAF
    Biochem Pharmacol; 2023 Nov; 217():115841. PubMed ID: 37820964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Tolerability of Adjunctive Intravenous Sodium Nitroprusside Treatment for Outpatients With Schizophrenia: A Randomized Clinical Trial.
    Brown HE; Freudenreich O; Fan X; Heard SO; Goff D; Petrides G; Harrington AL; Kane JM; Judge H; Hoeppner B; Fava M; Perlis RH
    JAMA Psychiatry; 2019 Jul; 76(7):691-699. PubMed ID: 30916714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sodium nitroprusside is effective in preventing and/or reversing the development of schizophrenia-related behaviors in an animal model: The SHR strain.
    Diana MC; Peres FF; Justi V; Bressan RA; Lacerda ALT; Crippa JA; Hallak JEC; Abilio VC
    CNS Neurosci Ther; 2018 Jul; 24(7):624-632. PubMed ID: 29656549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of sodium nitroprusside on psychotic symptoms and spatial working memory in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial.
    Stone JM; Morrison PD; Koychev I; Gao F; Reilly TJ; Kolanko M; Mohammadinasab A; Kapur S; McGuire PK
    Psychol Med; 2016 Dec; 46(16):3443-3450. PubMed ID: 27655012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oligopeptidases activity in bipolar disorder: Ndel1 and angiotensin I converting enzyme.
    Dal Mas C; Carvalho MS; Marins LA; Yonamine CM; Cordeiro Q; McIntyre RS; Mansur RB; Brietzke E; Hayashi MAF
    J Affect Disord; 2019 Feb; 244():67-70. PubMed ID: 30321766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium nitroprusside treatment for psychotic symptoms and cognitive deficits of schizophrenia: A randomized, double-blind, placebo-controlled trial.
    Wang X; Zhao J; Hu Y; Jiao Z; Lu Y; Ding M; Kou Y; Li B; Meng F; Zhao H; Li H; Li W; Yang Y; Lv L
    Psychiatry Res; 2018 Nov; 269():271-277. PubMed ID: 30170285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment-resistant schizophrenia - A RCT on the effectiveness of repeated-dose sodium nitroprusside.
    Adelino MPM; Nunes MV; Nunes MFQ; Costa ER; Ajub E; Mitrovitch MPB; Ushirohira JM; Quarantini LC; Hallak JCE; Lacerda ALT
    Schizophr Res; 2021 May; 231():70-72. PubMed ID: 33773362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the role of Ndel1 oligopeptidase activity in congenital Zika syndrome: Potential predictor of congenital syndrome endophenotype and treatment response.
    Christoff RR; Nani JV; Lessa G; Rabello T; Rossi AD; Krenn V; Higa LM; Tanuri A; Garcez PP; Hayashi MAF
    J Neurochem; 2023 Aug; 166(4):763-776. PubMed ID: 37497817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of sodium nitroprusside in the acute dizocilpine (MK-801) animal model of schizophrenia.
    Wang X; Ding S; Lu Y; Jiao Z; Zhang L; Zhang Y; Yang Y; Zhang Y; Li W; Lv L
    Brain Res Bull; 2019 Apr; 147():140-147. PubMed ID: 30772438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased expression of NDEL1 and MBP genes in the peripheral blood of antipsychotic-naïve patients with first-episode psychosis.
    Ota VK; Noto C; Santoro ML; Spindola LM; Gouvea ES; Carvalho CM; Santos CM; Xavier G; Higuchi CH; Yonamine C; Moretti PN; Abílio VC; Hayashi MA; Brietzke E; Gadelha A; Cordeiro Q; Bressan RA; Belangero SI
    Eur Neuropsychopharmacol; 2015 Dec; 25(12):2416-25. PubMed ID: 26476704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elucidating the relationship between DISC1, NDEL1 and NDE1 and the risk for schizophrenia: evidence of epistasis and competitive binding.
    Burdick KE; Kamiya A; Hodgkinson CA; Lencz T; DeRosse P; Ishizuka K; Elashvili S; Arai H; Goldman D; Sawa A; Malhotra AK
    Hum Mol Genet; 2008 Aug; 17(16):2462-73. PubMed ID: 18469341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of overexpression of Giα proteins and nitroxidative stress contribute to sodium nitroprusside-induced attenuation of high blood pressure in SHR.
    Hossain E; Sarkar O; Li Y; Anand-Srivastava MB
    Physiol Rep; 2018 Mar; 6(6):e13658. PubMed ID: 29595917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside: a randomized, double-blind, placebo-controlled trial.
    Hallak JE; Maia-de-Oliveira JP; Abrao J; Evora PR; Zuardi AW; Crippa JA; Belmonte-de-Abreu P; Baker GB; Dursun SM
    JAMA Psychiatry; 2013 Jul; 70(7):668-76. PubMed ID: 23699763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.